Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives

doi:10.3748/wjg.v25.i38.5773

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 25, Issue 38

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11408)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

968

WORD

267

HTML

7109

Figures (1-1)

203

Tables (1-1)

152

Sum=8699

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

416

Download

633

Sum=1049

Publishing Process of This Article

Item

Count

Browse

656

Download

1004

Sum=1660

Oct 14, 2019 (publication date) through Apr 26, 2024

Times Cited of This Article

Times Cited (63)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Oct 14, 2019; 25(38): 5773-5788
Published online Oct 14, 2019. doi: 10.3748/wjg.v25.i38.5773

Table 1 Ongoing phase II/III target trials in advanced gastric cancer

Study	Line	Control arm	Experimental arm	Target	NCT number
JACOB	1^st	Placebo +	Pertuzumab +	HER2	NCT01774786
		Trastuzumab +	Trastuzumab +
		Chemotherapy	Chemotherapy
ID NUMBER:11-166	2^nd	-	Afatinib +	HER2	NCT01522768
ID NUMBER:11-166	2^nd	-	Paclitaxel	HER2	NCT01522768
NIEGA	2^nd	-	Irinotecan +	EGFR	NCT03400592
NIEGA	2^nd	-	Nimotuzumab	EGFR	NCT03400592
ENRICH	2^nd	Irinotecan	Irinotecan +	EGFR	NCT01813253
ENRICH	2^nd	Irinotecan	Nimotuzumab	EGFR	NCT01813253
CheckMate-649	1^st	Oxaliplatin +	- Nivolumab + Oxaliplatin +	PD-1, CTLA-4	NCT02872116
		Oxaliplatin +	Fluoropyrimidine
		Fluoropyrimidine	Fluoropyrimidine
		Fluoropyrimidine	- Ipilimumab + Nivolumab
ATTRACTION-4	1^st	Placebo + Oxaliplatin + S-1/Capecitabine	Oxaliplatin + S-1/Capecitabine + Nivolumab	PD-1	NCT02746796
JAVELIN Gastric 100	1^st	Maintenance 1^st line	Avelumab	PD-L1	NCT02625610
KEYNOTE-062	1^st	Platin/fluoropyrimidine	- Pembrolizumab	PD-1	NCT02494583
KEYNOTE-062	1^st	Platin/fluoropyrimidine	- Pembrolizumab + Platin/fluoropyrimidine	PD-1	NCT02494583
SPOTLIGHT	1^st	Oxaliplatin +	Zolbetuximab + Oxaliplatin +	CLDN18.2	NCT03504397
SPOTLIGHT	1^st	Fluoropyrimidine	Fluoropyrimidine	CLDN18.2	NCT03504397
ILUSTRO	1^st/3^rd	-	- Zolbetuximab monotherapy, 3^rd line	CLDN18.2	NCT03505320
ILUSTRO	1^st/3^rd	-	- Zolbetuximab + FOLFOX, 1^st line	CLDN18.2	NCT03505320
GLOW	1^st	Oxaliplatin +	Zolbetuximab + Oxaliplatin +	CLDN18.2	NCT03653507
GLOW	1^st	Capecitabine	Capecitabine	CLDN18.2	NCT03653507
ANGEL	3^rd	BSC	Apatinib	VEGFR-2	NCT03042611
INTEGRATE II	3^rd	Placebo	Regorafenib	VEGFR1-3,	NCT02773524
				FGFR,
				PDGFR-β RAF, RET and KIT

JACOB: A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 Positive Metastatic Gastroesophageal Junction or Gastric Cancer; ID NUMBER:11-1669: Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer; NIEGA: Study of Nimotuzumab and Irinotecan as Second Line With Recurrent or Metastatic Gastric Adenocarcinoma; ENRICH: Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer; CheckMate649: Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer; ATTRACTION-4: Study of ONO-4538 in Gastric Cancer; JAVELIN: Gastric 100Avelumab in First-Line Maintenance Gastric Cancer; KEYNOTE-062: Study of Pembrolizumab as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma; SPOTLIGHT: A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction Cancer; ILUSTRO: A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab in Participants With Claudin 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction Adenocarcinoma; GLOW: A Study of Zolbetuximab Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma; ANGEL: Efficacy and Safety Trial of Apatinib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Patients With Gastric Cancer; INTEGRATEII: A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer, Best supportive care; HER2: Human epidermal growth factor receptor 2; EGFR: Epidermal growth factor receptor; PD-L1: Programmed death ligand 1; PD-1: Programmed cell death protein 1; CTLA-4: Cytotoxic T-lymphocyte-associated antigen 4; CLDN18.2: Claudine-18.2; VEGFR1-3: Vascular endothelial growth factor receptor 1-3; FGFR: Fibroblastic growth factor receptor; PDGFR-β: Platelet-derived growth factor receptor beta; RAF: Serine/threonine-specific protein kinases RAF; RET: Rearranged during transfection; KIT: Tyrosine-protein kinase Kit.

Citation: Pellino A, Riello E, Nappo F, Brignola S, Murgioni S, Djaballah SA, Lonardi S, Zagonel V, Rugge M, Loupakis F, Fassan M. Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives. World J Gastroenterol 2019; 25(38): 5773-5788
URL: https://www.wjgnet.com/1007-9327/full/v25/i38/5773.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i38.5773